Genome Editing Market End-user Overview, Key Opportunities, Growth Drivers and Restraint Analysis

Genome Editing Industry Overview

The global genome editing market size is expected to reach USD 19.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 22.9% from 2021 to 2028. The success of CRISPR/Cas9 technology in 2020 coupled with technological advances in Transcription Activator-Like Effector Nucleases (TALENs) and Zinc-finger Nucleases (ZFNs) with respect to efficiency has driven the market.

Research communities are exploring the potential of gene-modification tools like CRISPR as a potential rapid screening solution for the COVID-19 genome. For instance, in December 2020, researchers from Gladstone Institutes developed a CRISPR-based test that uses smartphones to deliver results. Similarly in June 2020, researchers from Stanford University have developed -PAC-MAN a gene-modification tool based on CRISPR technology. This tool destroys SARS-CoV-2 inside human cells.

Genome Editing Market Segmentation

Grand View Research has segmented the global genome editing market on the basis of technology, delivery method, application, mode, end-use, and region:

Based on the Technology Insights, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganucleases, and Others

• The CRISPR/Cas9 segment dominated the market and accounted for the largest revenue share of 40.2% in 2020.
• The limitations of CRISPR technology have increased in applications of the TALEN technique in some hard-to-edit genomic regions.

Based on the Delivery Method Insights, the market is segmented into Ex-vivo and In-vivo

• The ex-vivo delivery method segment dominated the market and accounted for the largest revenue share of 57.2% in 2020.
• The in-vivo gene delivery method accounted for lower revenue generation because of challenges that occurred during the process such as off-target effects.
• However, focused efforts are being taken to overcome the challenges with growing clinical trials focused on easy target tissues using in-vivo delivery.

Based on the Application Insights, the market is segmented into Genetic Engineering and Clinical Applications

• The developments in gene editing systems have revolutionized the genetic engineering space, with cell line engineering at the forefront, accounting for the largest revenue share of 58.8% in 2020.
• The usage of CRISPR gene editing in human-induced pluripotent stem cells (hiPSCs) related programs has important implications in stem cell research for the treatment of various diseases.
• The clinical application segment dominated the market and accounted for the significant revenue share in 2020.

Based on the Mode Insights, the market is segmented into Contract and In-house

• The contract-based genome editing segment dominated the market and accounted for the largest revenue share of 51.9% in 2020.
• The high cost of associated infrastructure coupled with increasing collaborations between market entities has resulted in a significant market share of contract services in the global market.

Based on the End-use Insights, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes, and Contract research organizations

• The biotechnology and pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 48.4% in 2020.
• On the other hand, government research and academic institutes are anticipated to witness healthy growth in the near future owing to the increasing uptake of gene-editing technologies in university-level projects.

Genome Editing Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

Most of the players are undertaking licensing agreements with technology developers to enhance their market presence.

Some prominent players in the global Genome Editing market include:

• Merck KGaA
• Cibus, Recombinetics, Inc.
• Sangamo
• Editas Medicine
• Precision Biosciences
• CRISPR Therapeutics
• Intellia Therapeutics, Inc.
• Caribou Biosciences, Inc.
• Cellectis S.A.
• AstraZeneca

Order a free sample PDF of the Genome Editing Market Intelligence Study, published by Grand View Research.